Compare Sanofi SA (SNY) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard S&P 500 ETF — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Vanguard S&P 500 ETF trades at $715.59 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 18.9× Sanofi SA's market cap, and Sanofi SA pays a 6.01% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vanguard S&P 500 ETF for 55 Days on average.
| SNY | VOO | |
|---|---|---|
Market Cap | $95.18B | $1.80T |
Volume | 2,995,646 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $52.34 | $716.17 |
52-Week Low | $39.51 | $580.93 |
Typical Hold Time | 94 Days | 55 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
VOO trades at $715.59 with a slight 0.16% daily gain, showing technical bullish momentum with strong moving average support. The ETF maintains its position as a core S&P 500 holding with upcoming dividend distribution. Recent news highlights its role in long-term wealth building and recession resilience, though short interest increased 46.9% in September according to Defense World data.
VOO offers diversified exposure to large-cap US equities with low expense ratio advantages. The main investment case centers on long-term market participation, though investors face S&P 500 valuation concerns and potential earnings growth slowdown from 35% to 15% in 2027 as noted by 24/7 Wall Street. Dividend yield remains modest compared to income-focused alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
